2023-01-25 09:00:00

VPM oversees clinical trial and translational project management Positive Phase I data of client Memo Therapeutics AG

Logo GlobeNewswire

HANNOVER, Germany, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vakzine Projekt Management GmbH (VPM), a German drug development consultancy and service provider supporting small and medium pharma and biotech companies with its exceptional expertise spanning the complete pharmaceutical value chain from drug discovery to clinical development, marketing authorization and market access, today announced the successful completion of a clinical client project for Memo Therapeutics AG (MTx), Switzerland. The project included a PhaseI clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients. VPM oversaw the clinical trial and performed translational project management, whereas the Australian cooperation partner and contract research organization (CRO) Accelagen managed the trial, yielding positive results, with all endpoints met.

In this phase I, single-blind, partially randomized, placebo-controlled clinical trial, 40 healthy adult volunteers were administered single and multiple ascending intravenous doses of AntiBKV (ClinicalTrials.gov: NCT05358106). No relevant adverse events were seen up to the highest dose of 2000mg and pharmacokinetics were found to be normal and linear. MTx plans to submit an Investigational New Drug Application (IND) during the first quarter 2023 to initiate a multicenter study in the U.S..

Dr. Karsten Fischer, Chief Executive Officer of Memo Therapeutics AG, commented: VPM has supported our drug development from the very start, throughout Phase I, and helped us to conclude our trial efficiently, cost-effectively and successfully. The broad expertise and commitment of VPM made the trial run smoothly, within budget and on time. As a next step we plan to initiate a multicenter study in the U.S.. For similar development projects in the future, we will continue to count on VPMs support.

CEO and Founder of Accelagen, Greg Plunkett, added: We know VPM as trusted cooperation partner, and together we realized the efficient execution of this clinical program. We have seen that their expertise and strong collaboration facilitates fast and seamless development in all important geographies of the world. The outcomes we have achieved together exemplifies our shared values and commitment to making a difference to the future of healthcare.

Our work with Memo Therapeutics, especially on AntiBKV, has driven the transformation of a ground-breaking idea into a life-saving potential medication, based on the in-depth knowledge and experience of successful pharmaceutical development strategies across a broad range of indications within VPM. Furthermore, our reliable, internationally renowned CRO partner Accelagen supports us in our endeavors, with highly efficient trial and regulatory processes and international standards, said Dr. Leander Grode, Managing Director of VPM. By engaging with our expanding network of cooperation partners, we aim to increase our offerings in clinical trials and our commitment to supporting clients in their pipeline development and building value in their companies.

BKV is a wide-spread virus persisting in approximately 80-90 % of the population. While clinically not relevant in healthy individuals, the virus is often reactivated in immunosuppressed patients. Reactivation has been shown to be a frequent cause of kidney transplant deterioration and rejection. AntiBKV is intended to provide an acute treatment, reduce the viral load below the detection limit and thus, for the first time, provide a causal treatment of polyomavirus-associated nephropathy.

About VPM
Vakzine Projekt Management GmbH (VPM) is a German consultancy and service provider established in 2002. Within the last two decades, VPM has successfully managed and consulted the development of promising biopharmaceutical candidates, ranging from small molecules, recombinant proteins up to gene-modified live vaccines and ATMPs. For its customers from the pharmaceutical industry, academic research and small biotechnology companies, VPM helped develop their products from preclinical phase through clinical phases I-III and approval, managing the processes more cost-effectively and with higher success probabilities. Read more about VPM on: https://www.vpm-consult.com/en/

About Memo Therapeutics AG
Memo Therapeutics AG (MTX) is a clinical-stage biopharma company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and cancer. MTxs lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. This infection can lead to loss of kidney function, as well as organ failure and rejection. Memos pipeline consists of additional therapeutic antibodies focusing on infectious diseases, such as cytomegalovirus, as well as undisclosed immuno-oncology targets.
The pipeline derives from MTxs industry-leading throughput and functional screening capabilities, which can cover the entire antibody repertoire. Using its immortal cell libraries and unique nano droplet technology, MTx identifies and isolates the most potent antibodies based on functionality at an unprecedent rate, including discovering ultra-rare antibodies that competing technologies fail to identify. MTx is a private company located in Schlieren/Zurich, Switzerland.

About Accelagen
Accelagen is a leading Contract Research Organisation (CRO) that works with innovative clients both in Australia and across the globe, employing a unique approach to process and people to co-create meaningful outcomes that have a tangible impact on the future of human health and wellness.
Accelagen is underpinned by the desire and courage to do things differently. Guided by purpose, the company continues to attract like-minded experts who share this desire and who won't settle for the status quo. By bringing attention to the human side of what can be a very clinical field, Accelagen leads the way in using data and research to solve for social and environmental issues that will change the world.



Dr. Leander Grode, CEO
Tel: +49 511 16 99 08 19

Media contact

MC Services AG
Dr. Brigitte Keller
Tel.: +49 89 210 228 0

Continue read on globenewswire.com

Logo EIN Presswire
HealthPress Release2023-03-19 07:15:00
Medication Management System market was worth USD 2.6 Bn in 2022. It is projected to grow at a CAGR of 11.2% and is to reach USD 7.2 Bn from 2023 to 2032....

Logo GlobeNewswire
SciencePress Release2023-03-20 07:01:00
Dr. David Bearss, an oncology researcher and biotech start-up founder, spoke with CancerVAX CEO Ryan Davies on the future of oncology therapeutics LEHI,...

Logo Nasdaq
Business / FinanceBy Validea2023-03-19 19:20:30
Below is Validea's guru fundamental report for PROVENTION BIO INC ( PRVB ). Of the 22 guru strategies we follow, PRVB rates highest using our Quantitative...

Logo The Business Journals
Business / Finance2023-03-20 03:23:53
Three leaders within the company were appointed to new roles.

Logo PR Newswire
HealthPress Release2023-03-18 18:38:00
MUMBAI, India and PRINCETON, N.J., March 18, 2023 /PRNewswire/ -- Concert Pharmaceuticals ("Concert"), a company recently acquired by Sun Pharmaceutical...

Logo EIN Presswire
Autologous Cell Therapy Market 2023 This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the...

Logo Benzinga
Business / FinanceBy Business Wire2023-03-14 20:58:00
Repare Therapeutics Inc. ("Repare" or the "Company") RPTX, a leading clinical-stage precision oncology company, today announced the data from the Phase I/II...

Logo PR Newswire
HealthPress Release2023-03-20 07:00:00
LONDON, March 20, 2023 /PRNewswire/ -- PL Diagnostics Ltd (PremaLabs UK) today announced that its portable Point of Care Test (POCT) analyser, the PL Mini...

Logo PR Newswire
HealthPress Release2023-03-14 12:17:00
BOCA RATON, Fla. and RICHLAND, Wash., March 14, 2023 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a contract development and...

Logo GlobeNewswire
SciencePress Release2023-03-15 20:01:00
Cash runway extended through 2025 with $ 250 million in non-dilutive funding over pasteight months TAMARACK study design modified with objective of...

Logo GlobeNewswire
EconomyPress Release2023-03-20 06:10:00
Active pharmaceutical ingredients industry is anticipated to register 6.5% CAGR between 2023 and 2032 due to growing prevalence of chronic diseases and...

Logo PR Newswire
HealthPress Release2023-03-15 20:05:00
WALTHAM, Mass., March 15, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced that data from the Phase 1 portion of the ongoing...

Logo PR Newswire
HealthPress Release2023-03-15 20:05:00
CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 Addition of GPR40 agonist discovery...

Logo GlobeNewswire
SciencePress Release2023-03-14 20:30:00
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2...

Logo Nasdaq
Business / FinanceBy Validea2023-03-19 13:15:39
Below is Validea's guru fundamental report for MEDPACE HOLDINGS INC ( MEDP ). Of the 22 guru strategies we follow, MEDP rates highest using our Twin Momentum...

Logo Benzinga
Business / FinanceBy Business Wire2023-03-16 13:05:00
n-Lorem has industrialized the process to scale up to meet substantial demand with major efforts underway to streamline all aspects of its process n-Lorem is...

Logo EIN Presswire
HealthPress Release2023-03-18 14:46:07
PRINCETON, NEW JERSEY, UNITED STATES, March 18, 2023 / EINPresswire.com / -- Practice Pro, a prominent Practice Management, electronic medical record (EMR)...

Logo Benzinga
Business / FinanceBy Business Wire2023-03-20 01:00:00
Updated results from phase 1 trial, including first presentation of data from a cohort of patients with EGFR-mutated metastatic non-small cell lung cancer,...

Logo GlobeNewswire
TechnologyPress Release2023-03-20 06:00:00
Company announcement no. 4 / 2023 20 March 2023 The Annual General Meeting 2023 of Trifork Holding AG (the AGM ) will take place on 12 April 2023, at 10:00...

Logo NewsFileCorp
Press Release2023-03-20 06:45:00
Vancouver, British Columbia--(Newsfile Corp. - March 20, 2023) - Eastern Platinum Limited (TSX: ELR) ( JSE: EPS) (" Eastplats " or the " Company ") announced...